Congenital, hereditary, and neonatal diseases and abnormalities

Anti-CGRPs associated with increased risk of early pregnancy loss, study finds

Researchers found that, after adjustment, the estimated absolute increase in risk of early pregnancy loss associated with exposure to the medicines was 4.2 percentage points.…

No clear increase in pregnancy risks after GLP-1 exposure, study suggests

The study authors warned that the findings should not be read as proof that GLP-1 medicines are safe to use during pregnancy, with further research needed.…

Post-finasteride syndrome: pharmacists must lead the conversation on patient safety

We would not accept a tooth-whitening procedure that carried a risk of suicide, persistent sexual dysfunction and irreversible neurological harm. Why is it being accepted with finasteride?…

Case-based learning: sedating medicines, breastfeeding and safe sleeping advice

How pharmacists can help to reduce the risk of sudden infant death syndrome and provide more holistic care for breastfeeding families when advising on the use of sedating medicines.…

Health news round-up: puberty blockers, oral GLP-1s and inequalities in neonatal care

A weekly summary of important developments in pharmacy and health news that you may have missed.…

Patient safety commissioner to approach PM over ‘disappointing’ delay to valproate compensation

Henrietta Hughes said that nearly two years after publishing ‘The Hughes report’, patients harmed by valproate use are still waiting for a decision on financial redress.…

MHRA sets out plans to speed up access to rare disease therapies

The Medicines and Healthcare products Regulatory Agency said “the rulebook for rare disease therapies will be overhauled" to make it quicker and easier to get therapies tested and approved.…

Patient safety commissioner pushes government on valproate redress almost two years after report

Exclusive: In a statement made to The Pharmaceutical Journal, Henrietta Hughes has urged the government to provide a full response to recommendations made in her February 2024 report.…

Valproate in pregnancy reaches lowest level yet, data suggest

Sodium valproate prescriptions for women and girls aged 12 to 54 years have almost halved since measures were introduced to reduce prescribing in April 2018.…

First ‘NICE-curated’ clinical guideline announced

The National Institute for Health and Care Excellence said the Duchenne muscular dystrophy guideline would be followed by others to provide “useful and useable guidance in an efficient, timely and sustainable manner”.…